PRECEDE: Transforming the Early Detection and Prevention of Pancreatic Cancer

In this episode of The Onco’Zine Brief Peter Hofland, Ph.D. talks with Diane Simeone, MD, the Committee Chair and Principal Investigator and Executive Committee Chair of the PRECEDE Consortium. Simeone is also the Laura and Isaac Perlmutter Professor of Surgery, Department of Surgery at NYU Grossman School of Medicine, Professor, Department of Pathology at NYU Grossman School of Medicine, Director, Pancreatic Cancer Center and Associate Director, Translational Research, Perlmutter Cancer Center. Hofland also talks with Tom Schoenherr, the Chief Executive Officer of Ambry Genetics, one of the participating industry partners of the PRECEDE program. In today’s episode Simeone, Schoenherr, and Hofland talk about Pancreatic Cancer and a new, international collaborative initiative called The Pancreatic Cancer Early Detection or PRECEDE Consortium, which includes more than 35 leading academic medical centers across the globe. The PRECEDE Consortium wants to transform the early detection and prevention of pancreatic cancer, with the aim of increasing the 5-year survival rate from 10 percent today to 50 percent within the next 10 years In addition to academic centers, the PRECEDE Consortium includes industry partners who bring their expertise and resources in genetic testing, pathology, and imaging as well as in information technology to support the program; to determine who is at an elevated risk for developing pancreatic cancer, define that risk, and invite those with a higher risk to participate in a state-of-the-art clinical screening program. The PRECEDE Consortium analyzes and standardizes data curated through an integrated diagnostics platform called LATTICE™, a platform that runs on Amazon Web Services or AWS. LATTICE uses Amazon HealthLake, a HIPAA-eligible service that helps organizations store, transform, query, and analyze health data, and will help researchers and clinicians gain new genomic insights for detecting and preventing pancreatic cancer. About The Onco'Zine Brief The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio. For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: http://www.oncozine.com to download our Media Kit or visit Patreon at https://www.patreon.com/theoncozinebrief to support the program. For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.